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Schizotypy and psychosis-like experiences from
recreational cannabis in a non-clinical sample
E. Barkus and S. Lewis*
The University of Manchester, Manchester, UK
Background. The relationship between cannabis use and psychosis is still a matter for debate. Accounting for the
individual differences in subjective experiences to recreational cannabis use in the general population may hold some
clues to the aetiological relationship between cannabis and psychotic symptoms. We hypothesized that schizotypy
would account for the individual differences in subjective experiences after cannabis use but not in patterns of use.
Method. In a sample of 532 young people who had used cannabis at least once, we examined the relationship between
the Cannabis Experiences Questionnaire (CEQ) and the Schizotypal Personality Questionnaire (SPQ). Additionally, we
examined the psychometric properties of the CEQ.
Results. We replicated our previously reported findings that schizotypy was associated with increased psychosis-like
experiences and after-effects, but also found that high-scoring schizotypes reported more pleasurable experiences when
smoking cannabis. Using new subscales derived from principal components analysis (PCA), we found that the psy-
chosis-like items were most related to varying rates of schizotypy both during the immediate use of cannabis and in the
after-effects of cannabis use. High-scoring schizotypes who used cannabis experienced more psychosis-like symptoms
during and after use.
Conclusions. Our results suggest that cannabis use may reveal an underlying vulnerability to psychosis in those with
high schizotypal traits.
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Introduction
In patients with established schizophrenia, rec-
reational cannabis use has been reported to increase
relapse and symptom severity (Linszen et al. 1994 ;
Baigent et al. 1995). In addition, administration of
the principal psychoactive substance in cannabis, D9-
tetrahydrocannabinol (D9-THC), transiently exacer-
bates the positive, negative and cognitive symptoms
in stabilized patients with schizophrenia (D’Souza
et al. 2005).
There is also evidence that cannabis use is a risk
factor for the initial onset of psychosis. In a longitudi-
nal community study, van Os et al. (2002) demon-
strated that baseline cannabis use predicted the
emergence of psychotic symptoms and need for care
due to psychotic symptoms at follow-up. A recent re-
view of the longitudinal studies to date reported that
regular cannabis seems to increase the risk of de-
veloping schizophrenia (Degenhardt & Hall, 2006).
However, these studies do not determine the nature
of the relationship between cannabis and psychosis :
are those who are psychosis prone attracted to using
cannabis (an association model), does cannabis use
directly increase proneness to psychosis (a causal
model), or is there another factor that links psychosis
proneness and cannabis use (an indicator-variable
model ; Dumas et al. 2002)? A number of reviews have
tried to address the evidence for causal and associ-
ation models (e.g. Hall et al. 2004 ; Verdoux et al. 2005;
Degenhardt & Hall, 2006 ; Fergusson et al. 2006).
The conclusion reached by authors on the basis
of current data is that, in individuals with an under-
lying predisposition to psychosis, cannabis use may
precipitate a psychotic episode, but it is difficult to
argue for a direct and large causal role for cannabis
use in psychosis. However, Ferdinand et al. (2005) also
highlight the possibility that the nature of the re-
lationship between cannabis use and psychotic symp-
toms may be bidirectional. This is a conclusion that
could be reached by most association studies, par-
ticularly those that do not attempt to control for base-
line levels of psychotic symptoms or psychosis
proneness.
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One way to explore the relationship between psy-
chotic symptoms and cannabis use is to examine the
impact of cannabis use in healthy individuals with psy-
chometrically defined psychosis proneness, or schizo-
typy. Schizotypal trait has been reported to be higher
in relatives of patients with schizophrenia (e.g. Appels
et al. 2004), may share some of the same risk genetic
loci as schizophrenia (Fanous et al. 2007) and may also
lead to increased cognitive deficits in relatives of
patients with schizophrenia (Diwadkar et al. 2006).
Schizotypy is characterized by attenuated psychotic
symptoms that comprise both positive (unusual beliefs
and perceptual experiences) and negative (social
anxiety and withdrawal) features. Pre-existing schizo-
typy has been reported to increase the risk of psychotic
states from cannabis use (Henquet et al. 2005) and also
modulate sensitivity to the effects of D9-THC (Henquet
et al. 2006). Although cannabis use per se has been re-
ported to increase schizotypy scores (Kwapil et al.
1996 ;Williams et al. 1996 ;Moss et al. 2001 ; Skosnik et al.
2001 ; Dumas et al. 2002), these results have not been
consistent (Schiffman et al. 2005 ; Earleywine, 2006).
An alternative and perhaps more ecologically valid
approach is to examine the experiences that individ-
uals report after using cannabis rather than placing
any emphasis on full psychotic syndromes. Henquet
et al. (2006) and D’Souza et al. (2004) tested the effects
of D9-THC in healthy individuals ; however, D9-THC is
only one component of cannabis, and other ingredients
may be involved in the recreational effects of cannabis.
In addition, the effects of cannabis may be environ-
mentally modulated and administration of the D9-
THC in a controlled and artificial environment may
not produce the same effects as when it is used natu-
ralistically. This naturalistic approach has been taken
in two previous studies. First, Verdoux et al. (2003)
used experience sampling, a method of charting sub-
jective experience at random points during the day to
demonstrate that those with high psychosis vulner-
ability (defined by a structured interview) were more
likely than those with low psychosis proneness to
report unusual perceptual experiences and thoughts
following recreational cannabis use. Second, we
have previously reported an association between high
schizotypy score, a measure of psychosis proneness,
and recreational cannabis-induced psychosis-like ex-
periences and subsequent ‘after-effects ’, using the
newly developed Cannabis Experiences Questionnaire
(CEQ; Barkus et al. 2006). Given that there are indi-
vidual differences in people’s self-reported responses
to cannabis, it is important to try to determine the
possible mechanisms that may underpin these differ-
ences in experience ; particularly as it is becoming clear
that individuals differ in their risk for experiencing
psychotic symptoms following cannabis.
The current study aimed to replicate the findings of
Barkus et al. (2006) in a larger sample and also to refine
the psychometric properties of the CEQ. Specifically,
we were interested in comparing the effects of extreme
schizotypy scores on experiences from cannabis use.
We hypothesized (i) that schizotypy score would not
be related to patterns of cannabis use in terms of
whether used or not, age at first use, or frequency of
use, but that (ii) individuals with high schizotypy
scores would report increased levels of psychosis-like
symptoms and subsequent after-effects with cannabis
use compared to mean- or low-scoring schizotypes.
Method
Participants
Participants were drawn from a sample of 760 uni-
versity students [mean age 22 (S.D.=4) years ; males
38%] recruited using electronic advertisements either
emailed to them or as pop-up messages when they
logged onto their university system. The sample for
this study comprised 532 university students who re-
ported they had used cannabis at least once in their
lifetime. A total of 49.7% of the sample were current
users of cannabis, while 50.3% classed themselves as
past users of cannabis. The frequency of cannabis use
for the whole sample was: once or twice only 13.4%;
no more than a few times each year 22%; at least once
a month 12.6%; at least once a week 27.2%, and every
day 24.9%. The majority of the participants smoked
cannabis during the evening (82.4%), while 14.6%
smoked cannabis frequently during the day and night,
and only 3.1% reported smoking cannabis only during
the day. Other drugs used by participants are dis-
played in Table 1. Participants were completing a
variety of undergraduate or postgraduate studies at
one of three universities in North-West England.
Participants were not asked about psychiatric diag-
nosis or previous mental health problems.
Measures
Schizotypy (psychosis proneness)
Participants completed the Schizotypal Personality
Questionnaire (SPQ; Raine, 1991) online. The ques-
tionnaire is based on the diagnostic criteria for schizo-
typal personality disorder and produces a total score
and scores on three dimensions : Cognitive Perceptual
(CP), Interpersonal (I) and Disorganized (D).
Cannabis Experiences Questionnaire (CEQ; Barkus
et al. 2006)
The CEQ is a 55-item self-report scale that is divided
into three subscales. The Pleasurable Experiences
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(18 items) and Psychosis-Like Experiences subscales
(25 items) examine immediate responses to cannabis
and an After-Effects subscale once the initial ‘high’
from the cannabis has abated (12 items). Participants
indicated how frequently they had had the experi-
ences on the CEQ by responding on a five-point scale
(Rarely or never, From time to time, Sometimes Yes
Sometimes No, More often than not, Almost always or
always). The frequency of cannabis use and age at first
use were also assessed.
Procedure
Participants were initially contacted using remote
means (either email or pop-up message). The initial
recruitment email requested participants to take part
in research addressing personality, unusual experi-
ences and cannabis use. The recruitment email stated
that the researchers wanted both cannabis and non-
cannabis users to approach the web page. Participants
approached the web-mounted SPQ and CEQ ques-
tionnaires under their own volition. All participants
completed the SPQ first, and then followed with de-
tails of previous drug use before completing the CEQ.
Participants completed the questionnaires in their own
time, under conditions determined by the participant ;
no researchers were present at the time participants
completed the questionnaires. Participants were told
that the information they provided would be anony-
mous and confidential and collected for research pur-
poses only. Participants were not paid to complete the
questionnaires. The questionnaires were used as the
recruitment for a multi-staged study so participants
were asked to provide an email address. They were
provided with the first author’s email address for any
questions that they had. Participants were able to give
informed consent and were told that by submitting
their results they were agreeing to the use and storage
of their responses.
Statistical analysis
The results were analysed using SPSS version 12 (SPSS
Inc., Chicago, IL, USA). A conservative Bonferroni ap-
proach to significance levels was taken, where mul-
tiple tests were used to examine a research question.
The required significance level to be reached and the
sample size used are stated separately for each analy-
sis. The normality of the data was assessed by ex-
amining histograms, skewness and kurtosis figures.
For the group analysis where there were two groups,
t tests were used, and for group differences with three
groups, independent variable ANOVAs were used.
Taking a conservative approach, Scheffé post-hoc com-
parisons were performed to determine which groups
were significantly different from one another.
The subscales for the CEQ reported in the paper by
Barkus et al. (2006) were produced on the basis of face
validity rather than statistical analysis. Therefore, to
determine the structure of the questionnaire items
from a statistical perspective, principal components
analysis (PCA) was used. A scree plot was used to
determine the number of components or factors to be
extracted from the data. An oblimin rotation was used
because conceptually wewould expect the experiences
to be related to one another. Cronbach’s a coefficient
was used to determine the internal consistency of the
items for the new subscales, with a value of 0.7 being
considered adequate.
Results
Patterns of cannabis and drug use and schizotypy
There was no relationship between frequency of can-
nabis use and scores on the SPQ for the total score or
the subscales. There was no relationship between age
of first cannabis use and SPQ total. The relationship
between having smoked cannabis and current/past
cannabis use and psychosis proneness were examined
using independent t tests ; the Bonferroni-corrected
significance value required to be reached to qualify for
significance was 0.013. Participants who had smoked
cannabis at least once (n=532) had a highermean score
on the Disorganized dimension from the SPQ than
thosewho had not (n=228) [t=4.05, df=758, p<0.001 ;
had smoked cannabis : 7.36 (S.D.=4.10) ; had not
smoked cannabis : 6.03 (S.D.=4.24)]. Additionally, there
was a trend for participants who described themselves
as current (rather than past) cannabis users (n=263) to
have higher scores on the Disorganization dimension
than those who had stopped smoking cannabis
(n=266) [t=2.40, df=527, p=0.017; past smokers :
6.96 (S.D.=4.05) ; current smokers : 7.81 (S.D.=4.08)].
To determine whether there was a relationship be-
tween other recreational drugs used by participants
and schizotypy score, the effects of use of the drugs
displayed in Table 1 on schizotypy score were in-
vestigated. In line with correction for multiple com-
parisons, the significance level to be reach for these
analyses was 0.005. There was only a significant effect
upon the Disorganized dimension for speed [t=2.86,
df=758, p=0.004; users : 7.98 (S.D.=4.01) ; non-users :
6.78 (S.D.=4.19)] and cocaine [t=2.80, df=758,
p=0.005 ; users : 7.72 (S.D.=4.11) ; non-users : 6.73
(S.D.=4.18)].
Schizotypy score and Barkus et al. (2006) cannabis
experiences
Participants were divided into three groups according
to their total SPQ score : more than 1 S.D. above the
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Table 1. The use of other recreational drug and alcohol in the sample
Age first use,
mean (S.D.)
Ever
used (%)
Current
users (%) Frequency (%) When used (%)
Alcohol 14 (2.26) 81 95 Only once or twice 1.1 During the evening 94.1
About once a year 0.6 During the day 0.2
A few times each year 3.1 Frequently during
the day and night
5.7
About once a month 8.3
About once a week 24
More than once a week 50.3
Every day 12.5
Speed 17.61 (2.03) 15 2 Only once or twice 38.8 During the evening 88.8
About once a year 7.8 During the day 2.6
A few times each year 25 Frequently during
the day and night
8.6
About once a month 14.7
About once a week 5.2
More than once a week 5.2
Every day 3.4
Cocaine 18.83 (2.53) 23 38 Only once or twice 30.6 During the evening 96.1
About once a year 3.3 During the day 0.6
A few times each year 33.9 Frequently during
the day and night
3.4
About once a month 21.1
About once a week 7.8
More than once a week 1.7
Every day 1.7
Ecstasy 18.33 (2.92) 26 38 Only once or twice 18.5 During the evening 25.5
About once a year 5 During the day 0.7
A few times each year 33.5 Frequently during
the day and night
0.1
About once a month 23.5
About once a week 13.5
More than once a week 6
Mushrooms 18 (2.13) 18 36 Only once or twice 35.3 During the evening 67.6
About once a year 11 During the day 25.7
A few times each year 47.8 Frequently during
the day and night
6.6
About once a month 4.4
About once a week 0.7
More than once a week 0.7
Tobacco 14.63 (2.61) 11.2 64 Only once or twice 3.5 During the evening 23.5
A few times each year 1.2 During the day 14.1
About once a month 5.8 Frequently during
the day and night
62.4
About once a week 7
More than once a week 15.1
Every day 67.4
LSD 17.34 (2.05) 7 2 Only once or twice 28.6 During the evening 71.4
About once a year 16.1 During the day 21.4
A few times each year 37.5 Frequently during
the day and night
7.1
About once a month 12.5
About once a week 3.6
More than once a week 1.8
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mean (n=86), more than 1 S.D. below the mean
(n=95), and those around the mean (n=351). The
group differences on the CEQ were examined using a
series of one-way ANOVAs [means (and standard
deviations)] : Pleasurable Experiences [High 50.49
(11.01), Mean 46.30 (10.85), Low 44.23 (11.68)] ; Psy-
chosis-Like Experiences [High 61.40 (16.88), Mean
50.72 (16.26), Low 42.42 (13.44)] ; After-Effects [High
31.74 (11.15), Mean 26.34 (9.64), Low 22.08 (7.82)]. The
p value required to be reached for this analysis was
0.016. There was a significant effect of psychosis
proneness group on all the subscales from the CEQ.
For the Pleasurable Experiences subscale [F(2, 529)=
7.66, p=0.001], the High group reported more than the
Mean (p=0.007) and the Low (p=0.001) psychosis
proneness groups. All the three groups scored signifi-
cantly different from one another on the Psychosis-
Like Experiences subscale [F(2, 529)=32.27, p<0.001]
at above the 0.001% level of significance. For the After-
Effects subscale [F(2, 529)=22.86, p<0.001], the High
and Mean groups and Low and High groups differed
at above the 0.001% level, while the Mean and Low
differed significantly from one another at the 0.001%
level.
Psychometric properties of the CEQ
All the items from the CEQ were entered into an ex-
ploratory PCA with data from 532 participants who
had used cannabis at least once in their lifetime. From
examination of a scree plot of the eigenvalues for the
data, it seemed that four components would appro-
priately explain the data. The PCA was performed
with an oblique rotation to allow the components to
correlate. The analysis accounted for 47.5% of the total
variance. The items from the After-Effects subscale all
loaded onto one component, and as these items are ex-
amining the period following the high from cannabis,
unlike the rest of the items, it seemed appropriate to
enter the After-Effects items in a separate analysis.
Immediate effects of cannabis
The PCA was repeated with the After-Effects items
removed. From examining a scree plot it seemed that
two or three components described the data. The third
component comprised four items and only con-
tributed 5.52% to the total variance. Additionally,
when the internal consistency of the items were ex-
amined, Cronbach’s a only reached 0.57. Therefore,
Table 1 (cont.)
Age first use,
mean (S.D.)
Ever
used (%)
Current
users (%) Frequency (%) When used (%)
Solvents 14.71 (2.14) 0.9 0 Only once or twice 28.6 During the evening 42.9
A few times each year 14.3 During the day 42.9
About once a week 28.6 Frequently during
the day and night
14.3
More than once a week 14.3
Every day 14.3
Poppers 16.34 (2.22) 4 39 Only once or twice 24.1 During the evening 79.3
About once a year 3.4 During the day 6.9
A few times each year 48.3 Frequently during
the day and night
13.8
About once a month 10.3
More than once a week 13.8
MDMA 18.68 (1.87) 4 43 Only once or twice 42.9 During the evening 100
About once a year 7.1
A few times each year 25
About once a month 21.4
About once a week 3.6
Ketamine 18.62 (2.24) 5 44 Only once or twice 44.1 During the evening 87.9
About once a year During the day 6.1
A few times each year 29.1 Frequently during
the day and night
6.1
About once a month 8.8
About once a week 14.7
More than once a week 2.9
Every day
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the two-component solution was judged to be most
effective explanation of the data. The items are pre-
sented in Table 2. Loadings above 0.3 were taken to
be significant and a simple solution was sought
with the highest loading being taken as significant
if an item loaded onto both components. The Pattern
Matrix was used to determine the pattern of load-
ings because this matrix presents the loadings in-
dependent of the correlation between the two
components.
The solution accounted for 39.2% of the total vari-
ance, with Component 1 contributing 25.2% and Com-
ponent 2 14.0% of the variance. Only the item of
‘Sleepy’ did not load significantly on to either of the
components. Component 1 had a Cronbach’s a coef-
ficient of 0.93 and Component 2 had an a of 0.88 ;
therefore, both the components display more than
adequate internal consistency. The items on Compo-
nent 1 contain many of the symptoms that were pre-
viously on the Psychosis-Like Experiences subscale.
The items on Component 2 seem to represent largely
pleasant experiences, which may be an excessive
of everyday occurrence of emotions. The items on
Component 1 can be characterized by the title
‘Paranoid-dysphoric Experiences’ whereas Compo-
nent 2 items are explained by the term ‘Euphoric Ex-
periences’.
After-Effects
The items from the After-Effects subscale were entered
into a separate PCA. Examination of a scree plot de-
termined that the items would be adequately ex-
plained by extracting two components from the data.
An oblique rotation was used to allow the components
to correlate with one another. As with the previous
analysis, the Pattern Matrix was used to determine
which items loaded significantly onto each compo-
nent, loadings above 0.3 were taken as significant and
a simple solution was sought. The results from the
analysis are presented in Table 3.
The PCA explained 64.5% of the variance, with
Component 1 accounting for 51.9% of the variance
and Component 2 contributing 12.5% of the total
variance. Cronbach’s a coefficients demonstrated that
the components had adequate internal consistency
(Component 1, 0.92 ; Component 2, 0.80). However,
collapsing both components into the original After-
Effects subscale still produced an a value of 0.92.
The items on Component 1 can be characterized as
‘Amotivational after-effects ’ whereas Component 2
items can be appropriately labelled ‘Psychosis-like
after-effects ’.
To examine the intercorrelations between the sub-
scales, two-tailed levels of significance are presented
for the Pearson’s correlation coefficients in order to
take a conservative approach, considering the size
of the sample being used. The intercorrelations
Table 2. The item loadings for the two components extracted
from the items comprising immediate responses to cannabis
Com-
ponent 1
Com-
ponent 2
All powerful 0.177 0.478
Angry 0.527 x0.074
Anxious 0.777 x0.073
Auditory hallucinations 0.546 0.177
Being relaxed x0.281 0.571
Compulsive 0.569 0.129
Deluded 0.662 0.111
Depressed 0.646 x0.078
Disturbed in your thinking 0.770 x0.046
Ecstatic x0.036 0.696
Energized x0.127 0.488
Enhanced perceptual
awareness
0.172 0.634
Excited x0.131 0.581
Fearful 0.779 x0.123
Fearful that you are
going mad
0.732 x0.015
Feeling happy x0.271 0.639
Feel more creative 0.040 0.757
Full of ideas 0.128 0.742
Full of plans 0.074 0.681
Laid back x0.145 0.489
Lethargic 0.480 x0.032
Looking for excitement 0.027 0.638
Losing sense of reality 0.661 0.084
Nervy 0.781 x0.069
No longer knowing yourself 0.713 x0.033
Things not feeling right
on your skin
0.588 0.091
Obsessive 0.683 0.034
Out of body experiences 0.356 0.210
Paranoid 0.719 x0.019
Powerful 0.062 0.506
Rapid flow of thoughts 0.512 0.366
Reduced level of
consciousness
0.615 x0.054
Religious 0.157 0.364
Sad 0.607 x0.072
Sentimental 0.108 0.493
Slowing of time 0.530 0.056
Speech becomes slurred 0.501 x0.046
Threatened by an
unknown force
0.654 0.034
Uncomfortably sleepy 0.533 x0.166
Understand the world better 0.143 0.697
Visual hallucinations 0.522 0.081
Bold values indicate factor loadings taken to be significant.
1272 E. Barkus and S. Lewis
between the subscales were as follows (Pearson’s r) :
Amotivational after-effects significantly correlated
with Psychosis-like after-effects (0.63), Euphoric (0.18)
and Paranoid-dysphoric (0.54) experiences ; Psychosis-
like after-effects significantly correlated with Euphoric
(0.25) and Paranoid-dysphoric (0.69) experiences ;
and Paranoid-dysphoric and Euphoric experiences
(0.16) significantly correlated with one another. All
the correlations are significant above the 1% level.
Relationship between schizotypy and CEQ factors
As reported above, we have shown that those who
score highly on the psychosis score significantly dif-
ferent from Mean or Low schizotypes on their re-
ported experience with cannabis. A similar analysis
was performed with the PCA-derived subscales for
the CEQ. As before, participants were grouped ac-
cording to being ¡1 S.D. or around the mean on the
total score on the SPQ. The ANOVAs were signifi-
cantly different for the four subscales. However, the
F values were larger for the subscales for the immedi-
ate and after-effects that had the psychotic items on.
Scheffé post-hoc comparisons were performed to de-
termine which groups scored significantly different
from one another on the subscales. The means (and
standard deviations) for this analysis were : Paranoid-
dysphoric subscale [High 59.44 (16.72), Mean 48.74
(16.21), Low 40.42 (13.69)] ; Euphoric subscale [High
45.07 (10.76) ; Mean 40.94 (10.39) ; Low 39.42 (11.05)] ;
Amotivational after-effects [High 20.02 (7.36), Mean
17.57 (6.98), Low 14.75 (5.96)] ; and Psychosis-like
after-effects [High 11.70 (4.80), Mean 8.77 (3.71), Low
7.34 (2.62)]. For the Paranoid-dysphoric Experiences
subscale [F(2, 529)=32.52, p<0.001], the groups all
differed significantly from one another above the 1%
level of significance. On the Euphoric Experiences
subscale [F(2, 529)=7.17, p=0.001] the High and
Mean (0.005) and the High and Low (0.002) differed
significantly from one another. The High and Mean
(0.012), High and Low (>0.001) and Mean and Low
(0.002) groups differed significantly from one another
on the Amotivational after-effects subscale [F(2, 529)=
13.53, p<0.001]. For the Psychosis-like after-effects
subscale [F(2, 529)=32.32, p<0.001], the Mean and
Low groups differed from one another with a signifi-
cance value of 0.004, but the other groups differed at
above the 0.001% level of significance.
Discussion
Cannabis use and schizotypy
There was no relationship between schizotypy score
and frequency of cannabis use nor the age of first use
of cannabis. However, thosewhohad smoked cannabis
at least once had higher scores on the Disorganized
dimension from the SPQ than those who had not
smoked cannabis. There was also a trend for those
current cannabis users to have higher scores on the
Disorganized dimension compared to previous users.
This was against our initial hypothesis that schizotypy
status would not be related to patterns of cannabis use.
Two previous studies have reported a relationship
between cannabis use and disorganized schizotypal
symptoms (Dumas et al. 2002 ; Schiffman et al. 2005).
The Disorganized dimension of the SPQ comprises
items that measure odd behaviour and odd speech.
Dumas et al. (2002) reported that gender differences
could account for the relationship between disorgan-
ized schizotypal trait and cannabis use. Therefore,
gender was placed in an ANOVA as a covariate, with
cannabis use as the independent variable and the
Disorganized subscale as the dependent variable.
However, the difference between those who had and
those who had not smoked cannabis remained sig-
nificant. The relationship between disorganized schi-
zotypal traits and cannabis use deserves further study
especially because Schiffman et al. (2005) not only re-
plicated these findings but also reported that the dis-
organized symptoms preceded cannabis use. It is also
interesting that the two other recreational drugs
(speed and cocaine) that showed a lead to a significant
difference on the Disorganized dimension from the
SPQ both elevate levels of dopamine in the brain.
Perhaps the disorganized features of schizotypy are
particularly sensitive to fluctuations in dopamine, even
at levels that may not produce unusual perceptual
experiences. The disorganized features of schizotypy
Table 3. The component loadings for the items from the
After-Effects subscale from the Cannabis Experiences
Questionnaire (CEQ)
Component 1 Component 2
Disinhibited 0.297 0.360
Don’t want to do anything 0.889 x0.095
Generally slowed down 0.949 x0.125
Loss of motivation 0.916 x0.043
Thinking slowed down 0.816 0.013
Cannot concentrate 0.779 0.100
Slowing of time 0.494 0.322
Paranoid without reason x0.052 0.925
Suspicious without reason x0.082 0.952
Felt depersonalized 0.035 0.722
Cannot remember events 0.310 0.421
Have reduced attention 0.675 0.179
Bold values indicate factor loadings taken to be significant.
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are relatively underinvestigated, with greater empha-
sis being placed on the positive features ; however, the
current data suggest they may warrant further inves-
tigation.
Schizotypy and cannabis experiences
The PCA for the immediate effects from cannabis
use produced two components, Paranoid-dysphoric
Experiences and Euphoric Experiences, both with
high internal consistency. The items on each sub-
scale are reflected by their title, with the sympto-
matic effects from cannabis use appearing on the
Paranoid-dysphoric Experiences subscale and the
more expansive experiences from cannabis use charac-
terizing the Euphoric Experiences subscale. The in-
ternal consistency scores for the two subscales for
the after-effects from cannabis use also had high a
values, although when they were combined, the
Cronbach’s a coefficient for the after-effects items was
equally as high. The two subscales produced were:
Amotivational after-effects and Psychosis-like after-
effects.
Using the original subscales reported in Barkus et al.
(2006), participants with high schizotypy scores re-
ported higher levels of subjective experiences on all
factors. The previous findings were largely replicated,
with the exception that the high schizotypes also re-
ported higher levels of pleasurable experience, al-
though the mean difference between the three groups
is small and considerably less than that shown for
psychosis-like experiences.
However, examining the schizotypy group differ-
ences on the new subscales demonstrated an in-
teresting finding. Although the ANOVAs were all
significant for the four new subscales, the largest
F values and differentiation between the three groups
can be seen on the subscales that contain the psychotic
symptoms, that is the Paranoid-dysphoric from the
immediate experiences and the Psychosis-like after-
effects from cannabis use. These results suggest that,
although there appears to be no psychometric ad-
vantage to the two components that comprise the
after-effects experiences, it may be informative from a
hypothesis testing perspective to use the PCA-derived
subscales.
From the results in this paper it is possible to
argue for a causal relationship between cannabis
use and psychotic symptoms in those who express
high schizotypy. We cannot comment on associations
with diagnosable psychotic disorders as these data
were not available for the sample collected. In line
with Henquet et al. (2005), those with high schizotypy
seemed to be more sensitive to the effects from
cannabis use because they scored higher on all
the subscales from the CEQ. In the light of prev-
ious research, perhaps our results point towards dop-
amine sensitization as being a possible mechanism
for high schizotypes having more experiences with
cannabis per se and particularly more psychomimetic
effects.
Validation of cannabis experiences as expression of
psychosis proneness
It is now accepted that the psychotic experiences re-
ported in those who score highly on schizotypy mea-
sures are qualitatively similar to those reported in
patient samples (e.g. Honig et al. 1998). A similar ar-
gument could be applied to the clinical relevance and
validity for the psychotic experiences associated with
cannabis use. There is emerging clinical and exper-
imental evidence to suggest that the psychotic symp-
toms that result from cannabis use are of clinical
relevance and may indicate risk of underlying psycho-
pathology. The administration of the psychoactive
substance D9-THC to healthy volunteers was reported
to induce psychotic-like symptoms when given in-
travenously (D’Souza et al. 2004) and a psychosis
prodrome-like state when giving orally (Koethe et al.
2006). Sensitivity to the effects of D9-THC is modulated
by psychometric psychosis liability and genetic poly-
morphism (COMT) determined dopamine turnover in
the cortex (Henquet et al. 2006). Taken together, these
studies point to the manipulation of dopamine by D9-
THC underpinning the psychotic experiences associ-
ated with recreational cannabis use and also indicate
that D9-THC would be a useful experimental model of
psychosis. From a clinical perspective, 47.1% of those
seeking help for cannabis-induced psychosis were di-
agnosed with schizophrenia-spectrum disorder 1 year
after initial presentation (Arendt et al. 2005), suggest-
ing that psychotic responses to cannabis may also have
some predictive validity.
Limitations
The data from the current study were self-reported
and collected using the internet. Remote collection of
data has been questioned in terms of its validity and
reliability. The population means for the SPQ in the
current sample are similar to those reported by Raine
(1991). Additionally, we have previously used internet
data collection and validated responses at interview
(e.g. Barkus et al. 2007). Although participants had the
option to provide an email address (to take part in
later phases of the study), the results were largely
anonymous, which should have encouraged honest
reporting of schizotypal traits and cannabis experi-
ences. Self-reported rates of cannabis use have been
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shown to be highly correlated with biological mea-
sures (Fendrich et al. 2004). It was also made clear to
participants there would be no consequences for any
reported drug use. The high internal consistency
values for the CEQ subscales suggest that random re-
sponding was not taking place, or at least if it did, it
did not influenced the results. Internet data collection
permits the accumulation of a large number of re-
sponses in a relatively short period of time, which
holds both for psychometric validation and for identi-
fying individuals who score at the extremes of a per-
sonality trait. Extreme high-scoring schizotypes are
more likely to approach remote data collection meth-
ods. There is a possibility that such individuals would
have high levels of social anxiety and therefore avoid
face-to-face interactions but a computer interface
would appear more controllable and less intimidating
to them.
The validation of the items on the CEQ to date has
taken place in relatively young student samples.
Therefore, the measure needs to be considered in a
more heterogeneous general public sample next. In
particular, the patterns of cannabis use may be differ-
ent in a general population sample because its use may
have greater impact on daily life outside a student
culture. Additionally, although the predictive value of
the CEQ has been speculated upon here, this needs to
be formally tested in differentiating schizophrenia-
spectrum disorder patients from other clinical groups,
as well as being examined in terms of predicting
transition to psychosis in prodrome samples.
The current study has replicated previous findings
of an association between schizotypy and psycho-
pathological experiences and increased after-effects
from recreational cannabis use. The new PCA-derived
subscales suggest that it is the psychotic-like experi-
ences in response to cannabis use that differentiate
high-scoring schizotypes from mean- and low-scoring
schizotypes most strikingly. The results suggest that
the CEQ is a valid and useful instrument to further
elucidate the relationship between cannabis and psy-
chosis.
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